When: Q3 2026 beat-and-raise with HashiCorp contribution disclosure, no goodwill impairment discussion, and continued deleveraging

Then: Upgrade to Overweight with full re-engagement

SELL with 40-50% trim, retain residual position no more than 25% of intended weight, stop loss at $211

• Q2 deceleration from plus 7.6% to plus 1.1% is genuinely alarming, technical structure is broken
• Total cash return profile of approximately 8.4% (dividend plus buyback yield)
• FCF of $11.46 billion represents approximately 5.3% FCF yield on ~$218 billion market cap
• FCF declined 3 years: $12.12 billion to $11.76 billion to $11.46 billion
• IBM spent $8.3 billion on acquisitions in fiscal 2025 including HRL deal
• 28 consecutive years of dividend increases, FCF coverage of dividend approximately 1.8 times
• Debt of $65 billion, intangibles of $88.6 billion at 256% of equity, negative tangible book of minus $54 billion
• Interest coverage is 6.5 times, deferred revenue balance over $20 billion
• ROE of 34.5%, gross margin expanded from 54% (2021) to 58.2% (2025)
• Operating margin expanded from low-teens to 16.5%
• Beta of 0.7 provides defensive characteristic during regime transitions
• ATR compressed 56% from July spike of 16.75 to 7.38
• September 1 volume was 3.2 million shares against 30-day average of 6-7 million
• July 14 low was printed on 67 million shares
• Stop loss at $211 (July crash low) is well-placed major support level
• Re-entry requires confirmed close above 50-day SMA at $242 AND MACD cross with both lines positive
• Current ratio below 1 is a real structural risk but does not indicate doomed balance sheet

→ vs aggressive: Aggressive Analyst treats binary catalyst events as if downside is the only possible outcome, which is narrative capture and pattern-matching rather than risk management; HRL Laboratories is closed, Arm-based mainframe chip shipped August 24 with real product news, and Susquehanna specifically raised price target citing upcoming quantum catalysts

→ vs aggressive: Aggressive Analyst conflates strategic capital allocation with operational deterioration; the FCF decline is partly due to $8.3 billion in M&A spend, which is capital deployment not cash erosion; normalizing FCF for M&A spend shows underlying cash generation is stable

→ vs aggressive: Aggressive Analyst's comparison to AT&T and GE is cherry-picked; IBM has 28 consecutive years of dividend increases and FCF coverage of 1.8x versus those peers

→ vs aggressive: Low volume after sharp sell-off with stabilizing price is consolidation, not distribution; distribution happens on high volume breakdowns, and recent sessions show no follow-through selling on low volume

→ vs aggressive: Aggressive Analyst's plan to push trim beyond 50% and zero out residual position creates re-entry costs in both basis and taxes, and likely misses the next 5-10% move when it comes if IBM stages a relief rally on quantum news or constructive Q3 print

→ vs aggressive: Aggressive Analyst frames catalyst risk-reward as asymmetric to the downside (5% pop on good news, 10-15% drop on disappointment) but this assumes perfect timing of disappointment, which is impossible

→ vs neutral: Trader's re-entry trigger above $240 on rising volume would be buying into overhead supply; instead wait for confirmed close above 50-day SMA at $242 AND MACD cross with both lines positive for genuine regime confirmation

SELL with 45% position trim, 25% residual core (75% capital freed). Re-entry trigger: daily close above $240 on volume above 30-day average. Escalation trigger: close below $215 on above-average volume halves residual. Hedge residual with put spread (long $215, short $195). Q3 earnings (late October) is the primary decision point.

• SELL rating is correct per directional risk consensus; 45% trim recommended (midpoint between aggressive 60-70% and conservative 30-40%)
• ATR compression at 56% signals selling exhaustion, not distribution—challenging aggressive analyst's volume interpretation
• IBM spent $8.3 billion on acquisitions in fiscal 2025, explaining FCF decline from $12.12 to $11.46; not organically deteriorating
• Conservative analyst ignores OCF downtrend: $13.93 to $13.45 to $13.19 over three years
• Conservative analyst's dual re-entry trigger (50-day SMA at $242 plus MACD cross) requires 9-12% rally first—too expensive; single trigger at $240 is cleaner
• Aggressive analyst's catalyst dismissal is pattern-matching; HRL Labs deal closed, chip shipped, Susquehanna raised target
• Q3 earnings (late October) is the most important catalyst in the next 60 days—quantum milestones are binary but capped upside
• Options framing preferred over directional spot: put spread (long $215, short $195) hedges residual without overcommitting
• Dividend floor argument is weak—2.89% yield on 21% YTD decline is compensation for deterioration, not reward for quality
• Aggressive analyst's $211 stop-loss is well-placed; $215 is the escalation trigger for halving residual

→ vs aggressive: Volume argument misreads 3.2M shares on Sept 1 as distribution; ATR compressing 56% with price holding range signals selling exhaustion, not ongoing distribution. July 14 low on 67M shares is the actual distribution signature.

→ vs aggressive: M&A conflation: FCF decline from $12.12 to $11.46 reflects $8.3B strategic acquisition spend, not organic deterioration. Same metric at $230 (vs. $330) is accretive, not destructive.

→ vs aggressive: Catalyst asymmetry argument is narrative capture—HRL Labs closed, Arm-based mainframe chip shipped August 24, Susquehanna raised target. These are facts, not guaranteed disappointments.

→ vs conservative: ATR compression is neutral, not constructive—can precede volatility expansion in either direction. Treating neutral as bullish is confirmation bias.

→ vs conservative: Operating cash flow also declined: $13.93 to $13.45 to $13.19 over three-year window. OCF trend is mildly negative even backing out M&A.

→ vs conservative: Re-entry trigger requiring both 50-day SMA reclaim at $242 AND MACD cross means buying at $250+—residual is decorative rather than functional at that cost.

→ vs conservative: Dividend-floor argument is weak: 2.89% yield on 21% YTD decline is market paying to hold deteriorating asset, not rewarding quality. Dividend streaks are correlation, not causation.